Global and United States Peptide Cancer Vaccine Market Insights, Forecast to 2027

Global and United States Peptide Cancer Vaccine Market Insights, Forecast to 2027

Table of Contents
1 Study Coverage
1.1 Peptide Cancer Vaccine Product Introduction
1.2 Market by Pipeline
1.2.1 Global Peptide Cancer Vaccine Market Size Growth Rate by Pipeline
1.2.2 ITK-1
1.2.3 GRN-1201
1.2.4 TPIV200
1.2.5 TPIV110
1.2.6 UV1
1.2.7 Galinpepimut-S
1.2.8 TARP 27-35
1.2.9 HER-Vaxx
1.2.10 Vx-001
1.2.11 Others
1.3 Market by Application
1.3.1 Global Peptide Cancer Vaccine Market Size Growth Rate by Application
1.3.2 Breast Cancer
1.3.3 Lung Cancer
1.3.4 Melanoma
1.3.5 Prostate Cancer
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Peptide Cancer Vaccine Market Size, Estimates and Forecasts
2.1.1 Global Peptide Cancer Vaccine Revenue 2016-2027
2.1.2 Global Peptide Cancer Vaccine Sales 2016-2027
2.2 Global Peptide Cancer Vaccine, Market Size by Region: 2016 VS 2021 VS 2027
2.3 Peptide Cancer Vaccine Historical Market Size by Region (2016-2021)
2.3.1 Global Peptide Cancer Vaccine Retrospective Market Scenario in Sales by Region: 2016-2021
2.3.2 Global Peptide Cancer Vaccine Retrospective Market Scenario in Revenue by Region: 2016-2021
2.4 Peptide Cancer Vaccine Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Peptide Cancer Vaccine Sales Forecast by Region (2022-2027)
2.4.2 Global Peptide Cancer Vaccine Revenue Forecast by Region (2022-2027)
3 Global Peptide Cancer Vaccine Competitor Landscape by Players
3.1 Global Top Peptide Cancer Vaccine Manufacturers by Sales
3.1.1 Global Peptide Cancer Vaccine Sales by Manufacturer (2016-2021)
3.1.2 Global Peptide Cancer Vaccine Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Peptide Cancer Vaccine Manufacturers by Revenue
3.2.1 Key Peptide Cancer Vaccine Manufacturers Covered: Ranking by Revenue
3.2.2 Global Peptide Cancer Vaccine Revenue by Manufacturers (2016-2021)
3.2.3 Global Peptide Cancer Vaccine Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Peptide Cancer Vaccine Market Concentration Ratio (CR5 and HHI) (2016-2021)
3.2.5 Global Top 10 and Top 5 Companies by Peptide Cancer Vaccine Revenue in 2020
3.2.6 Global Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Peptide Cancer Vaccine Price by Manufacturers
3.4 Global Peptide Cancer Vaccine Manufacturing Base Distribution, Product Types
3.4.1 Peptide Cancer Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Peptide Cancer Vaccine Product Type
3.4.3 Date of International Manufacturers Enter into Peptide Cancer Vaccine Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Pipeline (2016-2027)
4.1 Global Peptide Cancer Vaccine Market Size by Pipeline (2016-2021)
4.1.1 Global Peptide Cancer Vaccine Sales by Pipeline (2016-2021)
4.1.2 Global Peptide Cancer Vaccine Revenue by Pipeline (2016-2021)
4.1.3 Peptide Cancer Vaccine Average Selling Price (ASP) by Pipeline (2016-2021)
4.2 Global Peptide Cancer Vaccine Market Size Forecast by Pipeline (2022-2027)
4.2.1 Global Peptide Cancer Vaccine Sales Forecast by Pipeline (2022-2027)
4.2.2 Global Peptide Cancer Vaccine Revenue Forecast by Pipeline (2022-2027)
4.2.3 Peptide Cancer Vaccine Average Selling Price (ASP) Forecast by Pipeline (2022-2027)
5 Breakdown Data by Application (2016-2027)
5.1 Global Peptide Cancer Vaccine Market Size by Application (2016-2021)
5.1.1 Global Peptide Cancer Vaccine Sales by Application (2016-2021)
5.1.2 Global Peptide Cancer Vaccine Revenue by Application (2016-2021)
5.1.3 Peptide Cancer Vaccine Price by Application (2016-2021)
5.2 Peptide Cancer Vaccine Market Size Forecast by Application (2022-2027)
5.2.1 Global Peptide Cancer Vaccine Sales Forecast by Application (2022-2027)
5.2.2 Global Peptide Cancer Vaccine Revenue Forecast by Application (2022-2027)
5.2.3 Global Peptide Cancer Vaccine Price Forecast by Application (2022-2027)
6 United States by Players, Pipeline and Application
6.1 United States Peptide Cancer Vaccine Market Size YoY Growth 2016-2027
6.1.1 United States Peptide Cancer Vaccine Sales YoY Growth 2016-2027
6.1.2 United States Peptide Cancer Vaccine Revenue YoY Growth 2016-2027
6.1.3 United States Peptide Cancer Vaccine Market Share in Global Market 2016-2027
6.2 United States Peptide Cancer Vaccine Market Size by Players (International and Local Players)
6.2.1 United States Top Peptide Cancer Vaccine Players by Sales (2016-2021)
6.2.2 United States Top Peptide Cancer Vaccine Players by Revenue (2016-2021)
6.3 United States Peptide Cancer Vaccine Historic Market Review by Pipeline (2016-2021)
6.3.1 United States Peptide Cancer Vaccine Sales Market Share by Pipeline (2016-2021)
6.3.2 United States Peptide Cancer Vaccine Revenue Market Share by Pipeline (2016-2021)
6.3.3 United States Peptide Cancer Vaccine Price by Pipeline (2016-2021)
6.4 United States Peptide Cancer Vaccine Market Estimates and Forecasts by Pipeline (2022-2027)
6.4.1 United States Peptide Cancer Vaccine Sales Forecast by Pipeline (2022-2027)
6.4.2 United States Peptide Cancer Vaccine Revenue Forecast by Pipeline (2022-2027)
6.4.3 United States Peptide Cancer Vaccine Price Forecast by Pipeline (2022-2027)
6.5 United States Peptide Cancer Vaccine Historic Market Review by Application (2016-2021)
6.5.1 United States Peptide Cancer Vaccine Sales Market Share by Application (2016-2021)
6.5.2 United States Peptide Cancer Vaccine Revenue Market Share by Application (2016-2021)
6.5.3 United States Peptide Cancer Vaccine Price by Application (2016-2021)
6.6 United States Peptide Cancer Vaccine Market Estimates and Forecasts by Application (2022-2027)
6.6.1 United States Peptide Cancer Vaccine Sales Forecast by Application (2022-2027)
6.6.2 United States Peptide Cancer Vaccine Revenue Forecast by Application (2022-2027)
6.6.3 United States Peptide Cancer Vaccine Price Forecast by Application (2022-2027)
7 North America
7.1 North America Peptide Cancer Vaccine Market Size YoY Growth 2016-2027
7.2 North America Peptide Cancer Vaccine Market Facts & Figures by Country
7.2.1 North America Peptide Cancer Vaccine Sales by Country (2016-2021)
7.2.2 North America Peptide Cancer Vaccine Revenue by Country (2016-2021)
7.2.3 U.S.
7.2.4 Canada
8 Asia Pacific
8.1 Asia Pacific Peptide Cancer Vaccine Market Size YoY Growth 2016-2027
8.2 Asia Pacific Peptide Cancer Vaccine Market Facts & Figures by Region
8.2.1 Asia Pacific Peptide Cancer Vaccine Sales by Region (2016-2021)
8.2.2 Asia Pacific Peptide Cancer Vaccine Revenue by Region (2016-2021)
8.2.3 China
8.2.4 Japan
8.2.5 South Korea
8.2.6 India
8.2.7 Australia
8.2.8 Australia
8.2.9 Indonesia
8.2.10 Thailand
8.2.11 Malaysia
8.2.12 Philippines
8.2.13 Vietnam
9 Europe
9.1 Europe Peptide Cancer Vaccine Market Size YoY Growth 2016-2027
9.2 Europe Peptide Cancer Vaccine Market Facts & Figures by Country
9.2.1 Europe Peptide Cancer Vaccine Sales by Country (2016-2021)
9.2.2 Europe Peptide Cancer Vaccine Revenue by Country (2016-2021)
9.2.3 Germany
9.2.4 France
9.2.5 U.K.
9.2.6 Italy
10 Latin America
10.1 Latin America Peptide Cancer Vaccine Market Size YoY Growth 2016-2027
10.2 Latin America Peptide Cancer Vaccine Market Facts & Figures by Country
10.2.1 Latin America Peptide Cancer Vaccine Sales by Country (2016-2021)
10.2.2 Latin America Peptide Cancer Vaccine Revenue by Country (2016-2021)
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Peptide Cancer Vaccine Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Peptide Cancer Vaccine Market Facts & Figures by Country
11.2.1 Middle East and Africa Peptide Cancer Vaccine Sales by Country (2016-2021)
11.2.2 Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2016-2021)
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E
12 Company Profiles
12.1 Boston Biomedical
12.1.1 Boston Biomedical Corporation Information
12.1.2 Boston Biomedical Description and Business Overview
12.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Boston Biomedical Peptide Cancer Vaccine Products Offered
12.1.5 Boston Biomedical Recent Development
12.2 Ultimovacs
12.2.1 Ultimovacs Corporation Information
12.2.2 Ultimovacs Description and Business Overview
12.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Ultimovacs Peptide Cancer Vaccine Products Offered
12.2.5 Ultimovacs Recent Development
12.3 BrightPath Biotherapeutics
12.3.1 BrightPath Biotherapeutics Corporation Information
12.3.2 BrightPath Biotherapeutics Description and Business Overview
12.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Products Offered
12.3.5 BrightPath Biotherapeutics Recent Development
12.4 TapImmune
12.4.1 TapImmune Corporation Information
12.4.2 TapImmune Description and Business Overview
12.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.4.4 TapImmune Peptide Cancer Vaccine Products Offered
12.4.5 TapImmune Recent Development
12.5 Immatics
12.5.1 Immatics Corporation Information
12.5.2 Immatics Description and Business Overview
12.5.3 Immatics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Immatics Peptide Cancer Vaccine Products Offered
12.5.5 Immatics Recent Development
12.6 Sellas
12.6.1 Sellas Corporation Information
12.6.2 Sellas Description and Business Overview
12.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Sellas Peptide Cancer Vaccine Products Offered
12.6.5 Sellas Recent Development
12.7 Imugene
12.7.1 Imugene Corporation Information
12.7.2 Imugene Description and Business Overview
12.7.3 Imugene Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Imugene Peptide Cancer Vaccine Products Offered
12.7.5 Imugene Recent Development
12.8 VAXON Biotech
12.8.1 VAXON Biotech Corporation Information
12.8.2 VAXON Biotech Description and Business Overview
12.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.8.4 VAXON Biotech Peptide Cancer Vaccine Products Offered
12.8.5 VAXON Biotech Recent Development
12.9 Generex Biotechnology
12.9.1 Generex Biotechnology Corporation Information
12.9.2 Generex Biotechnology Description and Business Overview
12.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Generex Biotechnology Peptide Cancer Vaccine Products Offered
12.9.5 Generex Biotechnology Recent Development
12.10 ISA Pharmaceuticals
12.10.1 ISA Pharmaceuticals Corporation Information
12.10.2 ISA Pharmaceuticals Description and Business Overview
12.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Products Offered
12.10.5 ISA Pharmaceuticals Recent Development
12.11 Boston Biomedical
12.11.1 Boston Biomedical Corporation Information
12.11.2 Boston Biomedical Description and Business Overview
12.11.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Boston Biomedical Peptide Cancer Vaccine Products Offered
12.11.5 Boston Biomedical Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Peptide Cancer Vaccine Industry Trends
13.2 Peptide Cancer Vaccine Market Drivers
13.3 Peptide Cancer Vaccine Market Challenges
13.4 Peptide Cancer Vaccine Market Restraints
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Peptide Cancer Vaccine Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables
Table 1. Global Peptide Cancer Vaccine Market Size Growth Rate by Pipeline, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of ITK-1
Table 3. Major Manufacturers of GRN-1201
Table 4. Major Manufacturers of TPIV200
Table 5. Major Manufacturers of TPIV110
Table 6. Major Manufacturers of UV1
Table 7. Major Manufacturers of Galinpepimut-S
Table 8. Major Manufacturers of TARP 27-35
Table 9. Major Manufacturers of HER-Vaxx
Table 10. Major Manufacturers of Vx-001
Table 11. Major Manufacturers of Others
Table 12. Global Peptide Cancer Vaccine Market Size Growth Rate by Application (2021-2027) & (K Doses)
Table 13. Global Peptide Cancer Vaccine Market Size by Region (K Doses) & (US$ Million), 2016 VS 2021 VS 2027
Table 14. Global Peptide Cancer Vaccine Sales by Regions (2016-2021) & (K Doses)
Table 15. Global Peptide Cancer Vaccine Sales Market Share by Regions (2016-2021)
Table 16. Global Peptide Cancer Vaccine Revenue by Regions (2016-2021) & (US$ Million)
Table 17. Global Peptide Cancer Vaccine Sales Forecast by Region (2022-2027) & (K Doses)
Table 18. Global Peptide Cancer Vaccine Sales Market Share Forecast by Region (2022-2027)
Table 19. Global Peptide Cancer Vaccine Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 20. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Region (2022-2027)
Table 21. Global Peptide Cancer Vaccine Sales by Manufacturers (2016-2021) (K Doses)
Table 22. Global Peptide Cancer Vaccine Sales Share by Manufacturers (2016-2021)
Table 23. Ranking of Global Top Peptide Cancer Vaccine Manufacturers by Revenue (US$ Million) in 2020
Table 24. Peptide Cancer Vaccine Revenue by Manufacturers (2016-2021) (US$ Million)
Table 25. Peptide Cancer Vaccine Revenue Share by Manufacturers (2016-2021)
Table 26. Global Peptide Cancer Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
Table 27. Global Peptide Cancer Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peptide Cancer Vaccine as of 2020)
Table 28. Key Manufacturers Peptide Cancer Vaccine Price (2016-2021) (USD/Dose)
Table 29. Peptide Cancer Vaccine Manufacturers Manufacturing Base Distribution and Headquarters
Table 30. Manufacturers Peptide Cancer Vaccine Product Type
Table 31. Date of International Manufacturers Enter into Peptide Cancer Vaccine Market
Table 32. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 33. Global Peptide Cancer Vaccine Sales by Pipeline (2016-2021) (K Doses)
Table 34. Global Peptide Cancer Vaccine Sales Share by Pipeline (2016-2021)
Table 35. Global Peptide Cancer Vaccine Revenue by Pipeline (2016-2021) (US$ Million)
Table 36. Global Peptide Cancer Vaccine Revenue Share by Pipeline (2016-2021)
Table 37. Peptide Cancer Vaccine Average Selling Price (ASP) by Pipeline (2016-2021) & (USD/Dose)
Table 38. Global Peptide Cancer Vaccine Sales Forecast by Pipeline (2022-2027) & (K Doses)
Table 39. Global Peptide Cancer Vaccine Sales Market Share Forecast by Pipeline (2022-2027)
Table 40. Global Peptide Cancer Vaccine Revenue Forecast V (2022-2027) & (US$ Million)
Table 41. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Pipeline (2022-2027)
Table 42. Global Peptide Cancer Vaccine Average Selling Price (ASP) Forecast by Pipeline (2022-2027) & (USD/Dose)
Table 43. Global Peptide Cancer Vaccine Sales by Application (2016-2021) (K Doses)
Table 44. Global Peptide Cancer Vaccine Sales Share by Application (2016-2021)
Table 45. Global Peptide Cancer Vaccine Revenue by Application (2016-2021) (US$ Million)
Table 46. Global Peptide Cancer Vaccine Revenue Share by Application (2016-2021)
Table 47. Peptide Cancer Vaccine Average Selling Price (ASP) by Application (2016-2021) & (USD/Dose)
Table 48. Global Peptide Cancer Vaccine Sales Forecast by Application (2022-2027) & (K Doses)
Table 49. Global Peptide Cancer Vaccine Sales Market Share Forecast by Application (2022-2027)
Table 50. Global Peptide Cancer Vaccine Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 51. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Application (2022-2027)
Table 52. Global Peptide Cancer Vaccine Average Selling Price (ASP) Forecast by Application (2022-2027) & (USD/Dose)
Table 53. United States Peptide Cancer Vaccine Sales (K Doses) of Key Companies (2016-2021)
Table 54. United States Peptide Cancer Vaccine Sales Share by Company (2016-2021)
Table 55. United States Peptide Cancer Vaccine Revenue (US$ Million) by Company (2016-2021)
Table 56. United States Peptide Cancer Vaccine Revenue Share by Company (2016-2021)
Table 57. United States Peptide Cancer Vaccine Sales (K Doses) by Pipeline (2016-2021)
Table 58. United States Peptide Cancer Vaccine Sales Share by Pipeline (2016-2021)
Table 59. United States Peptide Cancer Vaccine Revenue (US$ Million) Market Share by Pipeline (2016-2021)
Table 60. United States Peptide Cancer Vaccine Price (USD/Dose) by Pipeline (2016-2021)
Table 61. United States Peptide Cancer Vaccine Sales (K Doses) by Pipeline (2022-2027)
Table 62. United States Peptide Cancer Vaccine Sales Share by Pipeline (2022-2027)
Table 63. United States Peptide Cancer Vaccine Revenue (US$ Million) Market Share by Pipeline (2022-2027)
Table 64. United States Peptide Cancer Vaccine Revenue Share by Pipeline (2022-2027)
Table 65. United States Peptide Cancer Vaccine Price (USD/Dose) by Pipeline (2022-2027)
Table 66. United States Peptide Cancer Vaccine Sales (K Doses) by Application (2016-2021)
Table 67. United States Peptide Cancer Vaccine Sales Share by Application (2016-2021)
Table 68. United States Peptide Cancer Vaccine Revenue (US$ Million) Market Share by Application (2016-2021)
Table 69. United States Peptide Cancer Vaccine Price (USD/Dose) by Application (2016-2021)
Table 70. United States Peptide Cancer Vaccine Sales (K Doses) by Application (2022-2027)
Table 71. United States Peptide Cancer Vaccine Sales Share by Application (2022-2027)
Table 72. United States Peptide Cancer Vaccine Revenue (US$ Million) Market Share by Application (2022-2027)
Table 73. United States Peptide Cancer Vaccine Revenue Share by Application (2022-2027)
Table 74. United States Peptide Cancer Vaccine Price (USD/Dose) by Application (2022-2027)
Table 75. North America Peptide Cancer Vaccine Sales by Country (2016-2021) & (K Doses)
Table 76. North America Peptide Cancer Vaccine Sales Market Share by Country (2016-2021)
Table 77. North America Peptide Cancer Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 78. North America Peptide Cancer Vaccine Revenue Market Share by Country (2016-2021)
Table 79. Asia Pacific Peptide Cancer Vaccine Sales by Region (2016-2021) & (K Doses)
Table 80. Asia Pacific Peptide Cancer Vaccine Sales Market Share by Region (2016-2021)
Table 81. Asia Pacific Peptide Cancer Vaccine Revenue by Region (2016-2021) & (US$ Million)
Table 82. Asia Pacific Peptide Cancer Vaccine Revenue Market Share by Region (2016-2021)
Table 83. Europe Peptide Cancer Vaccine Sales by Country (2016-2021) & (K Doses)
Table 84. Europe Peptide Cancer Vaccine Sales Market Share by Country (2016-2021)
Table 85. Europe Peptide Cancer Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 86. Europe Peptide Cancer Vaccine Revenue Market Share by Country (2016-2021)
Table 87. Latin America Peptide Cancer Vaccine Sales by Country (2016-2021) & (K Doses)
Table 88. Latin America Peptide Cancer Vaccine Sales Market Share by Country (2016-2021)
Table 89. Latin Americaa Peptide Cancer Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 90. Latin America Peptide Cancer Vaccine Revenue Market Share by Country (2016-2021)
Table 91. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2016-2021) & (K Doses)
Table 92. Middle East and Africa Peptide Cancer Vaccine Sales Market Share by Country (2016-2021)
Table 93. Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 94. Middle East and Africa Peptide Cancer Vaccine Revenue Market Share by Country (2016-2021)
Table 95. Boston Biomedical Corporation Information
Table 96. Boston Biomedical Description and Business Overview
Table 97. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 98. Boston Biomedical Peptide Cancer Vaccine Product
Table 99. Boston Biomedical Recent Development
Table 100. Ultimovacs Corporation Information
Table 101. Ultimovacs Description and Business Overview
Table 102. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 103. Ultimovacs Product
Table 104. Ultimovacs Recent Development
Table 105. BrightPath Biotherapeutics Corporation Information
Table 106. BrightPath Biotherapeutics Description and Business Overview
Table 107. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 108. BrightPath Biotherapeutics Product
Table 109. BrightPath Biotherapeutics Recent Development
Table 110. TapImmune Corporation Information
Table 111. TapImmune Description and Business Overview
Table 112. TapImmune Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 113. TapImmune Product
Table 114. TapImmune Recent Development
Table 115. Immatics Corporation Information
Table 116. Immatics Description and Business Overview
Table 117. Immatics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 118. Immatics Product
Table 119. Immatics Recent Development
Table 120. Sellas Corporation Information
Table 121. Sellas Description and Business Overview
Table 122. Sellas Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 123. Sellas Product
Table 124. Sellas Recent Development
Table 125. Imugene Corporation Information
Table 126. Imugene Description and Business Overview
Table 127. Imugene Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 128. Imugene Product
Table 129. Imugene Recent Development
Table 130. VAXON Biotech Corporation Information
Table 131. VAXON Biotech Description and Business Overview
Table 132. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 133. VAXON Biotech Product
Table 134. VAXON Biotech Recent Development
Table 135. Generex Biotechnology Corporation Information
Table 136. Generex Biotechnology Description and Business Overview
Table 137. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 138. Generex Biotechnology Product
Table 139. Generex Biotechnology Recent Development
Table 140. ISA Pharmaceuticals Corporation Information
Table 141. ISA Pharmaceuticals Description and Business Overview
Table 142. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 143. ISA Pharmaceuticals Product
Table 144. ISA Pharmaceuticals Recent Development
Table 145. OncoTherapy Science Corporation Information
Table 146. OncoTherapy Science Description and Business Overview
Table 147. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 148. OncoTherapy Science Product
Table 149. OncoTherapy Science Recent Development
Table 150. Peptide Cancer Vaccine Market Trends
Table 151. Peptide Cancer Vaccine Market Drivers
Table 152. Peptide Cancer Vaccine Market Challenges
Table 153. Peptide Cancer Vaccine Market Restraints
Table 154. Peptide Cancer Vaccine Customers List
Table 155. Peptide Cancer Vaccine Distributors List
Table 156. Research Programs/Design for This Report
Table 157. Key Data Information from Secondary Sources
Table 158. Key Data Information from Primary Sources
List of Figures
Figure 1. Peptide Cancer Vaccine Product Picture
Figure 2. Global Peptide Cancer Vaccine Sales Market Share by Pipeline in 2020 & 2027
Figure 3. ITK-1 Product Picture
Figure 4. GRN-1201 Product Picture
Figure 5. TPIV200 Product Picture
Figure 6. TPIV110 Product Picture
Figure 7. UV1 Product Picture
Figure 8. Galinpepimut-S Product Picture
Figure 9. TARP 27-35 Product Picture
Figure 10. HER-Vaxx Product Picture
Figure 11. Vx-001 Product Picture
Figure 12. Others Product Picture
Figure 13. Global Peptide Cancer Vaccine Sales Market Share by Application in 2020 & 2027
Figure 14. Breast Cancer
Figure 15. Lung Cancer
Figure 16. Melanoma
Figure 17. Prostate Cancer
Figure 18. Others
Figure 19. Peptide Cancer Vaccine Report Years Considered
Figure 20. Global Peptide Cancer Vaccine Market Size, (US$ Million), 2016 VS 2021 VS 2027
Figure 21. Global Peptide Cancer Vaccine Market Size 2016-2027 (US$ Million)
Figure 22. Global Peptide Cancer Vaccine Sales 2016-2027 (K Doses)
Figure 23. Global Peptide Cancer Vaccine Market Size Market Share by Region: 2021 Versus 2027
Figure 24. Global Peptide Cancer Vaccine Sales Market Share by Region (2016-2021)
Figure 25. Global Peptide Cancer Vaccine Sales Market Share by Region in 2020
Figure 26. Global Peptide Cancer Vaccine Revenue Market Share by Region (2016-2021)
Figure 27. Global Peptide Cancer Vaccine Revenue Market Share by Region in 2020
Figure 28. Global Peptide Cancer Vaccine Sales Share by Manufacturer in 2020
Figure 29. The Top 10 and 5 Players Market Share by Peptide Cancer Vaccine Revenue in 2020
Figure 30. Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 31. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2016-2021)
Figure 32. Global Peptide Cancer Vaccine Sales Market Share by Pipeline in 2020
Figure 33. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2016-2021)
Figure 34. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline in 2020
Figure 35. Global Peptide Cancer Vaccine Sales Market Share by Application (2016-2021)
Figure 36. Global Peptide Cancer Vaccine Sales Market Share by Application in 2020
Figure 37. Global Peptide Cancer Vaccine Revenue Market Share by Application (2016-2021)
Figure 38. Global Peptide Cancer Vaccine Revenue Market Share by Application in 2020
Figure 39. United States Peptide Cancer Vaccine Sales Growth Rate 2016-2027 (K Doses)
Figure 40. United States Peptide Cancer Vaccine Revenue Growth Rate 2016-2027 (US$ Million)
Figure 41. United States Peptide Cancer Vaccine Market Share in Global Market 2016-2027
Figure 42. United States 5 and 10 Largest Peptide Cancer Vaccine Players Market Share by Revenue in Peptide Cancer Vaccine in 2020
Figure 43. United States Peptide Cancer Vaccine Revenue Share by Pipeline (2016-2021)
Figure 44. United States Peptide Cancer Vaccine Revenue Growth Rate by Pipeline in 2016 & 2020
Figure 45. United States Peptide Cancer Vaccine Revenue Share by Application (2016-2021)
Figure 46. United States Peptide Cancer Vaccine Revenue Growth Rate by Application in 2016 & 2020
Figure 47. North America Peptide Cancer Vaccine Sales Growth Rate 2016-2021 (K Doses)
Figure 48. North America Peptide Cancer Vaccine Revenue Growth Rate 2016-2021 (US$ Million)
Figure 49. North America Peptide Cancer Vaccine Sales Market Share by Country in 2020
Figure 50. North America Peptide Cancer Vaccine Revenue Market Share by Country in 2020
Figure 51. U.S. Peptide Cancer Vaccine Sales Growth Rate (2016-2021) (K Doses)
Figure 52. U.S. Peptide Cancer Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 53. Canada Peptide Cancer Vaccine Sales Growth Rate (2016-2021) (K Doses)
Figure 54. Canada Peptide Cancer Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 55. Europe Peptide Cancer Vaccine Sales Growth Rate 2016-2021 (K Doses)
Figure 56. Europe Peptide Cancer Vaccine Revenue Growth Rate 2016-2021 (US$ Million)
Figure 57. Europe Peptide Cancer Vaccine Sales Market Share by Country in 2020
Figure 58. Europe Peptide Cancer Vaccine Revenue Market Share by Country in 2020
Figure 59. Germany Peptide Cancer Vaccine Sales Growth Rate (2016-2021) (K Doses)
Figure 60. Germany Peptide Cancer Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 61. France Peptide Cancer Vaccine Sales Growth Rate (2016-2021) (K Doses)
Figure 62. France Peptide Cancer Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 63. U.K. Peptide Cancer Vaccine Sales Growth Rate (2016-2021) (K Doses)
Figure 64. U.K. Peptide Cancer Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 65. Italy Peptide Cancer Vaccine Sales Growth Rate (2016-2021) (K Doses)
Figure 66. Italy Peptide Cancer Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 67. Russia Peptide Cancer Vaccine Sales Growth Rate (2016-2021) (K Doses)
Figure 68. Russia Peptide Cancer Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 69. Asia Pacific Peptide Cancer Vaccine Sales Growth Rate 2016-2021 (K Doses)
Figure 70. Asia Pacific Peptide Cancer Vaccine Revenue Growth Rate 2016-2021 (US$ Million)
Figure 71. Asia Pacific Peptide Cancer Vaccine Sales Market Share by Region in 2020
Figure 72. Asia Pacific Peptide Cancer Vaccine Revenue Market Share by Region in 2020
Figure 73. China Peptide Cancer Vaccine Sales Growth Rate (2016-2021) (K Doses)
Figure 74. China Peptide Cancer Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 75. Japan Peptide Cancer Vaccine Sales Growth Rate (2016-2021) (K Doses)
Figure 76. Japan Peptide Cancer Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 77. South Korea Peptide Cancer Vaccine Sales Growth Rate (2016-2021) (K Doses)
Figure 78. South Korea Peptide Cancer Vaccine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 79. India Peptide Cancer Vaccine Sales Growth Rate (2016-2021) (K Doses)
Figu

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global BCG Vaccine Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 96

According to our LPI (LP Information) latest study, the global BCG Vaccine market size was valued at US$ 365.6 million in 2023. With growing demand in downstream market, the BCG Vaccine is forecast to a readjusted size of US$ 542.8 million by 2030 with a CAGR of 5.8% during review period. The research report highlights the growth potential of the global BCG Vaccine market. BCG Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing cost......

Global Peptide Cancer Vaccine Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 115

According to our LPI (LP Information) latest study, the global Peptide Cancer Vaccine market size was valued at US$ 535 million in 2023. With growing demand in downstream market, the Peptide Cancer Vaccine is forecast to a readjusted size of US$ 1978.2 million by 2030 with a CAGR of 20.5% during review period. The research report highlights the growth potential of the global Peptide Cancer Vaccine market. Peptide Cancer Vaccine are expected to show stable growth in the future market. How......

Global Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 101

Market Overview of Global Cancer Vaccine market: According to our latest research, the global Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Cancer Vaccine market was estimated at USD 7198.2 million, and it's anticipated to reach USD 33936.62 million in 2028, with a CAGR of 29.49% during the forecast years. A cancer vaccine is a type of immunotherapy that boost the body's natural defenses by stimulating the immune system to recognize and cur......

Global Lung Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 12-Dec-2023        Price: US 3380 Onwards        Pages: 102

Market Overview of Global Lung Cancer Vaccines market: According to our latest research, the global Lung Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Lung Cancer Vaccines market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Lung Cancer Vaccines,A cancer vaccine for lung cance This report covers a research time span from 2018 to 2028, and ......

Global Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 07-Dec-2023        Price: US 3380 Onwards        Pages: 105

Market Overview of Global Cancer Vaccines market: According to our latest research, the global Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Cancer Vaccines market was estimated at USD 5773.14 million, and it's anticipated to reach USD 15406.41 million in 2028, with a CAGR of 17.77% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Vacci......

Global Dendritic Cell Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 110

Market Overview of Global Dendritic Cell Cancer Vaccine market: According to our latest research, the global Dendritic Cell Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Dendritic Cell Cancer Vaccine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Dendritic cells (DC) are one of the major antigen presenting cells found in lymphoid organs. The main fu......

Global BCG Vaccine Market Research Report 2023, Forecast to 2028

Published: 14-Nov-2023        Price: US 2680 Onwards        Pages: 135

BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......

Global BCG Vaccine Professional Survey Report 2023, Forecast to 2028

Published: 14-Nov-2023        Price: US 3280 Onwards        Pages: 105

BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......

Infectious Vaccine Collaboration and Licensing Deals 2016-2023

Published: 01-Nov-2023        Price: US 3995 Onwards        Pages: 300

Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious vaccine deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of infectious vaccine deals from 2016 to 2023. The report provides a detailed understanding and analysis of how and why companies enter infectious vaccine deals. These deals tend to be multicomponent, starting with......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs